Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MET233 and MET097 · 1 trial · 1 indication
For Part A, B, C, D, E and G
| Arm | Type | Description |
|---|---|---|
| Part A Cohort | EXPERIMENTAL | Cohort participants will receive single co-administered ascending dose (SAD) of subcutaneous (SC) MET233 and SC MET097 or matched SC placebo. |
| Part B Cohort | EXPERIMENTAL | Cohort Participants will receive multiple ascending dose (MAD) of co-administered SC MET233 with SC MET097 or matched SC placebo. |
| Part C Cohort | EXPERIMENTAL | Cohort Participants will receive multiple doses of SC MET233 co-administered with SC MET097 or matched SC placebo in participants with T2DM. |
| Part D Cohort | EXPERIMENTAL | Cohort Participants will receive multiple doses of weekly and monthly (ie, every 4 weeks \[QM\]) co-administered SC MET233 with SC MET097, or matched SC placebo in participants with obesity. |
| Part E Cohort | EXPERIMENTAL | Cohort Participants will receive multiple dose QW-to-QM of SC MET233 co-administered with SC MET097 or matched SC placebo in participants with obesity. |
| Part G Cohort | EXPERIMENTAL | Cohort Participants will receive multiple dose cohort of QW and QM SC MET097 monotherapy or matched SC placebo in participants with obesity or overweight. |
| Name | Type | Description |
|---|---|---|
| MET233 and MET097 | DRUG | For subcutaneous administration |
| Placebo | OTHER | Sterile 0.9% (w/v) saline for subcutaneous administration. |
| MET097 | DRUG | For subcutaneous administration |
Inclusion Criteria: * Adult males or females aged 18 to 75 years (inclusive) at the time of screening. * BMI ≥27.0 kg/m2 and ≤38.0 kg/m2 (inclusive) at Screening for Parts A, B, and C, and ≥30.0 kg/m2 and ≤45.0 kg/m2 (inclusive) at Screening for Parts D and E. Have a BMI ≥27.0 kg/m2 and ≤45.0 kg/m2...
MET233 is an investigational monoclonal antibody being developed for obesity and obesity-related medical conditions, as well as for obesity and overweight. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
MET233 is a monoclonal antibody, a type of biologic designed to target specific molecules in the body. However, its precise molecular target has not been disclosed in available information, so its exact mechanism of action is not publicly detailed.
MET233 is being developed by Metsera, Inc., a biopharmaceutical company publicly traded under the ticker symbol MTSR. The company is conducting clinical trials to evaluate the drug's safety and efficacy in individuals with obesity or overweight.
MET233 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies. The ongoing Phase 1 trials are designed to assess safety, tolerability, and preliminary efficacy.
MET233 is being studied in two Phase 1 clinical trials. One trial, NCT06924320, is recruiting and evaluates MET233 in combination with MET097 in individuals with obesity or overweight with or without diabetes. Another trial, NCT07022977, has been completed and studied MET233 alone in individuals with obesity or overweight.
MET233 is not the same as MET097. MET233 is a separate investigational monoclonal antibody, while MET097 is a different drug candidate. They are being studied together in a combination trial, but they are distinct therapeutic agents.